MedPath

Prospective intra-individual comparison of the mpMRI versus 68Ga-PSMA11 PET/MRI in a blinded read to evaluate diagnostic accuracy in patients with prostate cancer

Phase 2
Recruiting
Conditions
Prostate Cancer
D011471
Registration Number
JPRN-jRCTs022220021
Lead Sponsor
Kojima Yoshiyuki
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
152
Inclusion Criteria

1) Patients who have given written consent to participate in the study
2) Prostate cancer patients diagnosed with adenocarcinoma by prostate biopsy
3) Patients aged 40 or over at the time of registration
4) Untreated prostate cancer patients
5) Patients who are scheduled to undergo radical prostatectomy as curative treatment

Exclusion Criteria

1) Patients with obvious distant metastasis by CT /bone scintigraphy.
2) Patients who are ineligible for MRI examination, such as having a metal-containing medical device embedded in their body and claustrophobia.
3) Patients with other active cancers other than prostate cancer.
4) Patients with contrast medium allergy to gadolinium.
5) Patients who are judged by the principal investigator to be inappropriate for inclusion in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Comparison of diagnostic accuracy in clinical T staging between 68Ga-PSMA-11 PET/MRI and mpMRI
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath